Despite $2B Deal, J&J's Risperdal Fight Rages On In Pa.

Law360, Philadelphia (November 8, 2013, 7:24 PM EST) -- Johnson & Johnson’s blockbuster $2.2 billion Risperdal settlement resolves off-label marketing claims over the anti-psychotic drug, but it will have little effect on product liability litigation in Pennsylvania, where plaintiffs attorneys expect the drugmaker to continue the fight against claims that the drug caused health problems in teenage boys.

The founding partner of Sheller PC, a firm representing plaintiffs in nearly 250 product liability cases pending in the Philadelphia Court of Common Pleas, said that he will be unable to use a guilty plea by J&J...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.